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therapy, rifaximin did not select for significant
resistance among gut flora when given for 3 days.
It is unlikely that rifaximin would stimulate the
development of rifampicin-resistant Mycobacteri-
um tuberculosis, since the drug remains largely in
the gut during short-term use for the treatment of
diarrhoea. Extra-intestinal tissues infected with
M. tuberculosis should not be exposed to signifi-
cant concentrations of the drug, and growth of
M. tuberculosis on media containing varying con-
centrations of rifaximin does not lead to the
selection of rifampicin-resistant strains [11].
In summary, rifaximin appears to be a suitable
drug for the management of travellers’ diarrhoea
[12] and other non-systemic, non-dysenteric en-
teric bacterial infections. This drug has now been
licensed for use in the USA.
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ABSTRACT
Escherichia coli isolates from urinary tract infec-
tions (UTIs) (n = 124), extra-urinary sites (n = 37)
and normal faecal samples (n = 51) were exam-
ined for the presence of virulence factors, inclu-
ding siderophores (aerobactin and enterobactin).
The proportion of aerobactin producers was
significantly higher in UTI (69.4%; p 0.001) and
extra-urinary samples (70.3%; p 0.007) than in
controls (41.2%), while the proportion of ente-
robactin producers was significantly lower in the
UTI samples than in the controls (p 0.027). In a
cutaneous infection model, aerobactin-positive
E. coli showed more growth than non-aerobactin
and non-enterobactin isolates, even when other
virulence factors were identical.
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Escherichia coli is one of the commonest microor-
ganisms found in urinary tract infections (UTIs).
Bacterial virulence is multifactorial, and the viru-
lence characteristics of E. coli have been studied in
UTIs and bacteraemia [1–3]. Among the proposed
virulence factors are fimbrial adhesins, haemoly-
sin, siderophores, serum resistance and inactive
serum resistance [4–8]. Iron compounds are
known to increase the growth of bacteria, and
enteric bacteria produce a catechol-type sidero-
phore, enterobactin, and a hydroxamate-type
siderophore, aerobactin, under conditions of iron
starvation in vitro [9–11]. The aim of this study
was to investigate the production of siderophores
and other virulence factors by E. coli isolates, and
to investigate the role of siderophores in patho-
genicity with a cutaneous infection model.
E. coli isolates from UTIs (n = 124) and from
extra-urinary infection sites (n = 37) were studied.
UTI was defined as > 105 CFU ⁄mL of urine.
Control isolates (n = 51) were obtained from the
faeces of healthy adults. All isolates were collec-
ted at the Pamukkale University Hospital of
Denizli, Turkey.
The method of Rabsch and Reissbrodt [10,11]
was used for detection of aerobactin and enterob-
actin, with Tris-succinate medium for aerobac-
tin and Vogel–Bonner medium for enterobactin.
Haemagglutination and mannose-resistant haem-
agglutination of human group O erythrocytes was
tested with a microplate haemagglutination tech-
nique. Detection of haemolysin production, a
serum resistance assay and tests for survival of
E. coli in inactivated serum were performed as
described previously [6–8].
To evaluate pathogenicity in mice, isolates were
selected that varied in siderophore status, but
which were all haemolysin-negative, mannose-
resistant haemagglutination-positive, and serum-
and inactive serum-resistant. BALB-c mice weigh-
ing 25–30 g were assigned randomly to the
following groups: (1) enterobactin-positive (E+)
(n = 5); (2) aerobactin-positive (A+) (n = 5); (3)
aerobactin- and enterobactin-positive (AE+)
(n = 5); and (4) aerobactin- and enterobactin-
negative (AE–) (n = 5). Bacterial suspensions
(200 lL of 108 CFU ⁄mL) were injected subcuta-
neously. After 24 h, abscesses and inflamed tis-
sues were removed and weighed. The tissues
were homogenised under sterile conditions, and
then diluted with 5 mL of sterile phosphate-
buffered saline. The diluted homogenates were
inoculated (10 lL) on to blood and eosin methy-
lene blue agar and incubated at 37C. After 24 h,
the number of bacteria ⁄ g of tissue was estimated.
For statistical analysis, the chi-square test with
continuity correction was used. The Kruskal–
Wallis and Mann–Whitney U-tests were used for
the subcutaneous infection model. A p value of
< 0.05 was considered significant.
The proportion of aerobactin producers
among the control faecal isolates (41.2%) was
significantly lower than for the UTI isolates
(69.4%; p 0.001) and extra-urinary samples
(70.3%; p 0.007) (Table 1). In contrast, the pro-
portions of enterobactin producers were 44.4%,
51.4% and 62.7% for UTI, extra-urinary and
faecal isolates, respectively; this was significantly
lower for the UTI isolates than for the controls
(p 0.027). The presence of other virulence factors
is shown in Table 1.
In the cutaneous infection model, E. coli growth
in the A+ group was significantly higher than in
the AE– group, and growth in the AE+ group was
significantly higher than in the AE– group
(p 0.028 and p 0.021, respectively) (Table 2). The
number of E+ isolates was higher than that of AE–
isolates, and the number of A+ isolates was higher
than that of E+ isolates, but neither difference
reached statistical significance (Table 2).
Table 1. Distribution of virulence factors among Escheri-
chia coli isolates from urinary tract infections, extra-urinary
sites and control faecal samples
Virulence factors
% UTI
isolates
(n = 124)
% Extra-urinary
isolates
(n = 37)
% Control
isolates
(n = 51)
Aerobactin 69.4 (p 0.001) 70.3 (p 0.007) 41.2
Enterobactin 44.4 (p 0.027) 51.4 62.7
Haemolysin 33.9 (p 0.001) 35.1 (p 0.004) 9.8
HA-positive 83.9 (p 0.011) 78.4 66.7
MRHA 56.5 (p 0.001) 54.1 (p 0.020) 29.4
Serum resistance 62.1 59.5 66.7
Inactivated serum resistance 87.1 75.7 (p 0.031) 92.2
UTI, urinary tract infection; HA, haemagglutination; MRHA, mannose-resistant
haemagglutination.
Table 2. Growth of Escherichia coli in the subcutaneous
infection model according to virulence factor status
Virulence factor status
Growth (log10 CFU ⁄ g)
n Median SEM Range
Aerobactin- and enterobactin-negative (AE–) 5 4.52 1.25 0–5.48
Aerobactin-positive (A+) 5 6.90a,b 0.39 5.15–7.10
Enterobactin-positive (E+) 5 5.39c 1.17 0–6.80
Aerobactin- and enterobactin-positive (AE+) 5 5.69d 0.31 5.33–7.10
ap 0.028 vs. AE–; bp 0.07 vs. E+ cp 0.245 vs. AE–; dp 0.021 vs. AE–.
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The presence of siderophores and other viru-
lence factors in Gram-negative bacteria has been
investigated previously [11–14]. In the present
study, the proportion of aerobactin-producing
E. coli isolates was significantly higher in the
UTI and extra-urinary samples, which is consis-
tent with the results of other studies [14,15]. Ruiz
et al. [2] found that production of aerobactin in
E. coli isolates from patients with nephritis was
higher than in isolates from patients with cystitis.
It was suggested that siderophore production
might be an important factor in the progression of
prostatitis and pyelonephritis. Vila et al. [16]
found that the iucD gene was more common in
E. coli isolates causing pyelonephritis than in
isolates causing cystitis.
In pathogenicity studies, intraperitoneal, sub-
cutaneous and intradermal routes of inoculation
have been used, as well as the ascending UTI
model [3,17–19]. The role of siderophores was
investigated in the present study with the subcu-
taneous route, as it was quick, easy and practical.
The role of aerobactin and other virulence factors
in pathogenicity has been studied previously in
mice [8,18,19]. Torres et al. [19] suggested that
TonB was required for iron uptake by uropatho-
genic E. coli in a mouse model of UTI, as TonB-
negative mutant isolates showed reduced
virulence. In a competitive assay, aerobactin and
enterobactin transport-defective isolates did not
grow in the kidney, and aerobactin transport-
defective but enterobactin-intact isolates did not
grow together with the wild-type isolates in the
kidney.
In the mouse model used in the present study,
E. coli A+ isolates showed more growth than the
AE– isolates, and AE+ isolates showed more
growth than the AE– isolates. E. coli A+ isolates
showed more growth than E+ isolates, but the
difference was not statistically significant. Mont-
gomerie et al. [8] suggested that aerobactin is a
more significant factor in bacteraemia in mice
than enterobactin. In another study, E. coli isolates
were assigned to three groups according to LD50.
In the most virulent group, aerobactin production
was 88%, compared to 24% in avirulent isolates
[20]. In the ascending pyelonephritis mouse
model, siderophore-producing isolates have
increased renal pathogenicity [21]. It has also
been shown that the number of aerobactin-pro-
ducing E. coli isolates decreases in the presence of
mouse monoclonal antibody to ferric aerobactin
in newborn calf sera [22].
In the present study, isolates that differed by
siderophore status were compared. Although
many virulence factors, including siderophores,
mannose-resistant fimbriae, haemolysin and ser-
um resistance, have important roles in pathogen-
esis, it was observed that specific siderophore
production affected extra-intestinal E. coli infec-
tion, even when other virulence factors were
identical. The present study indicated that
siderophores have an important role in the pro-
gress of infection, and that production of aerob-
actin may be more important than production of
enterobactin. Further studies with animal models
are necessary to clarify this.
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ABSTRACT
Between 1999 and 2001, 355 hospital laboratories
in Italy were asked to complete a questionnaire
addressing mycobacterial test methods, 1-year
workloads and laboratory safety features. Analy-
sis of the data showed that rapid methods for
mycobacterial testing were being used by most
larger laboratories; however, sub-optimal meth-
ods were still in use in small and medium-size
laboratories. In a country such as Italy, which has
a low prevalence of tuberculosis cases, imple-
mentation of rapid technologies, combined with
regionalisation of mycobacterial diagnostic servi-
ces, seems to be the most reasonable and cost-
effective strategy.
Keywords Diagnostic tests, Mycobacterium tuberculo-
sis, rapid methods, safety, survey
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Tuberculosis (TB) may be considered a global
emergency, with > 2 million people dying and 8
million new cases each year [1]. Although the
prevalence of TB in the industrialised world is
relatively low, outbreaks caused by multiresistant
strains of the Mycobacterium tuberculosis complex
(MTB) have occurred in hospitals, prisons and
shelters for homeless people, often involving
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